Juliana 0.02 mg / 0.15 mg
Oral contraceptive Juliana is used to prevent pregnancy and also change the lining of the uterus to prevent pregnancy from developing and change the mucus at the cervix (opening of the uterus) to prevent sperm (male reproductive cells) from entering. Juliana contains Ethinylestradiol- 0.02 mg, Desogestrel - 0.15 mg.
Ethinylestradiol is used in contraception, post menopausal osteoporosis (porous bones), hormone replacement therapy (hrt), failure of ovarian development and prostate cancer. Ethinylestradiol belongs to a class of medications called estrogens (female hormones). It is a synthetic form of the naturally occurring hormone and helps in development and maintenance of menstrual cycle. In post-menopausal women, it works by reducing the post-menopausal symptoms and risk of weakening bones and bone fracture.
Common side effects are: vomiting, nausea, swelling, abdominal pain, altered libido, breast tenderness, breast pain, burning sensation, constipation, depression, pain during periods, flatulence, hair loss, headache, heartburn, mood changes, skin rash, skin redness, vaginal burning sensation, vaginal discharge, weight loss, weight gain
Desogestrel is a type of the progestogen, a female sex hormone, and acts by preventing the egg cell from ripening. Desogestrel is a type of the progestogen, a female sex hormone, and acts by preventing the egg cell from ripening. Ethinyl Estradiol is used in contraception, post menopausal osteoporosis (porous bones), hormone replacement therapy (hrt), failure of ovarian development and prostate cancer.
Common side effects are: nausea, ovarian cysts, pain, skin lump, acne, breast pain, abnormal milky discharge from breast, breast secretion, decreased libido, difficulty in wearing contact lense, pain during periods, hair loss, headache, absence of menstrual periods, irregular menstrual cycle, mood changes, urticaria, vaginal infection, vomiting, fatigue, weight gain.
Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.
No review yet
No questions yet